{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Karaba AH"],"funding":["National Institute of Allergy and Infectious Diseases","National Institute of Diabetes and Digestive and Kidney Diseases","NIDDK NIH HHS","NIAID NIH HHS","National Cancer Institute","NCI NIH HHS","NIGMS NIH HHS"],"pagination":["1253-1260"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8983554"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["22(4)"],"pubmed_abstract":["Vaccine-induced SARS-CoV-2 antibody responses are attenuated in solid organ transplant recipients (SOTRs) and breakthrough infections are more common. Additional SARS-CoV-2 vaccine doses increase anti-spike IgG in some SOTRs, but it is uncertain whether neutralization of variants of concern (VOCs) is enhanced. We tested 47 SOTRs for clinical and research anti-spike IgG, pseudoneutralization (ACE2 blocking), and live-virus neutralization (nAb) against VOCs before and after a third SARS-CoV-2 vaccine dose (70% mRNA, 30% Ad26.COV2.S) with comparison to 15 healthy controls after two mRNA vaccine doses. We used correlation analysis to compare anti-spike IgG assays and focused on thresholds associated with neutralization. A third SARS-CoV-2 vaccine dose increased median total anti-spike (1.6-fold), pseudoneutralization against VOCs (2.5-fold vs. Delta), and neutralizing antibodies (1.4-fold against Delta). However, neutralization activity was significantly lower than healthy controls (p < .001); 32% of SOTRs had zero detectable nAb against Delta after third vaccination compared to 100% for controls. Correlation with nAb was seen at anti-spike IgG >4 Log<sub>10</sub> (AU/ml) on the Euroimmun ELISA and >4 Log<sub>10</sub> (AU/ml) on the MSD research assay. These findings highlight benefits of a third vaccine dose for some SOTRs and the need for alternative strategies to improve protection in a significant subset of this population."],"journal":["American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons"],"pubmed_title":["A third dose of SARS-CoV-2 vaccine increases neutralizing antibodies against variants of concern in solid organ transplant recipients."],"pmcid":["PMC8983554"],"funding_grant_id":["K23 AI157893","HHSN272201400007C","U01 AI138897","R01AI120938S1","K23AI157893","F32 DK124941","T32DK007713","R01 AI120938","K08AI156021","T32 GM136577","F32DK124941","K08 AI156021","K23 DK115908","K24 AI144954","U54 CA260492","K24AI144954","K23DK115908","U54CA260491","T32 DK007713"],"pubmed_authors":["Liang T","Blankson JN","Bailey JR","Rittenhouse AG","Abedon AT","Ruff JE","Tobian AAR","Alejo JL","Akinde O","Eby Y","Sitaras I","Boyarsky BJ","Garonzik-Wang JM","Cox AL","Warren DS","Zhu X","Thompson EA","Wang KH","Klein SL","Pekosz A","Segev DL","Karaba AH","Werbel WA"],"additional_accession":[]},"is_claimable":false,"name":"A third dose of SARS-CoV-2 vaccine increases neutralizing antibodies against variants of concern in solid organ transplant recipients.","description":"Vaccine-induced SARS-CoV-2 antibody responses are attenuated in solid organ transplant recipients (SOTRs) and breakthrough infections are more common. Additional SARS-CoV-2 vaccine doses increase anti-spike IgG in some SOTRs, but it is uncertain whether neutralization of variants of concern (VOCs) is enhanced. We tested 47 SOTRs for clinical and research anti-spike IgG, pseudoneutralization (ACE2 blocking), and live-virus neutralization (nAb) against VOCs before and after a third SARS-CoV-2 vaccine dose (70% mRNA, 30% Ad26.COV2.S) with comparison to 15 healthy controls after two mRNA vaccine doses. We used correlation analysis to compare anti-spike IgG assays and focused on thresholds associated with neutralization. A third SARS-CoV-2 vaccine dose increased median total anti-spike (1.6-fold), pseudoneutralization against VOCs (2.5-fold vs. Delta), and neutralizing antibodies (1.4-fold against Delta). However, neutralization activity was significantly lower than healthy controls (p < .001); 32% of SOTRs had zero detectable nAb against Delta after third vaccination compared to 100% for controls. Correlation with nAb was seen at anti-spike IgG >4 Log<sub>10</sub> (AU/ml) on the Euroimmun ELISA and >4 Log<sub>10</sub> (AU/ml) on the MSD research assay. These findings highlight benefits of a third vaccine dose for some SOTRs and the need for alternative strategies to improve protection in a significant subset of this population.","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Apr","modification":"2026-06-06T01:12:59.412Z","creation":"2025-04-05T18:50:52.546Z"},"accession":"S-EPMC8983554","cross_references":{"pubmed":["34951746"],"doi":["10.1111/ajt.16933"]}}